NeuroMetrix

NeuroMetrix, Inc. engages in the development and manufacture of diagnostic and therapeutic neurostimulation-based medical devices. It focuses on the sale of medical equipment and consumables. Its products include DPNCheck, Quell, and ADVANCE system. The company was founded by Shai N. Gozani in June 1996 and is headquartered in Woburn, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

NeuroMetrix reports Q2 revenue decline but shows promise in Quell line

NeuroMetrix faced revenue decline due to DPNCheck product line, offset by strong growth in the Quell product line.
Efficient cost management reflected in a solid gross margin rate of 64% and reduced operating expenses.
The company maintains a healthy financial position with significant working capital and liquid assets.
Strategic review aims to enhance shareholder value and explore new growth avenues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NeuroMetrix, Inc. engages in the development and manufacture of diagnostic and therapeutic neurostimulation-based medical devices. Its products include DPNCheck, Quell, and ADVANCE system. It also focuses on the sale of medical equipment and consumables. The company was founded by Shai N. Gozani in June 1996 and is headquartered in Woburn, MA.

NeuroMetrix Inc's (NASDAQ: NURO) Quell device has received Breakthrough Designation from the FDA to treat fibromyalgia symptoms in adults. Fibromyalgia is a common form of chronic pain accompanied by fatigue, sleep, cognitive and mood disturbances.

NeuroMetrix Stock Surges As Its Nerve Stimulator Scores FDA Breakthrough Designation For Fibromyalgia

NeuroMetrix (NURO) stock is surging higher on Tuesday after getting "Breakthrough Device Designation" from the FDA for Quell. The post NURO Stock: The ‘Breakthrough' News Rocketing NeuroMetrix Shares Higher Today appeared first on InvestorPlace.

NURO Stock: The ‘Breakthrough' News Rocketing NeuroMetrix Shares Higher Today

GEE Group

Ur-Energy

Which penny stocks are investors watching following yesterday's crash? The post 3 Penny Stocks Rocketing Higher on Space Race and S&P 500 Gain appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks Rocketing Higher on Space Race and S&P 500 Gain

WOBURN, Mass., July 15, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 second quarter financial results before the opening of the market on July 22, 2021. The Company will host a conference call at 8:00 a.m., Eastern Time on July 22, 2021 to discuss its financial results as well as business developments affecting the Company.

NeuroMetrix, Inc. Announces Date for Second Quarter 2021 Financial Results Conference Call

WOBURN, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that Quell technology will be used in a double-blinded, randomized, sham-controlled trial to determine whether transcutaneous electrical nerve stimulation (TENS) is an effective, acceptable and feasible method of pain relief in patients with NMOSD. The principal investigator is Michael Levy, M.D., Ph.D., Director, NMO Clinic and Research Laboratory, Massachusetts General Hospital, Boston, MA.

NeuroMetrix Reports that Quell® Technology is to be Evaluated for Neuromyelitis Optica Spectrum Disorder (NMOSD) in a Randomized Controlled Trial

NeuroMetrix Inc (NASDAQ: NURO) has reported that top-line results from a randomized controlled trial of Quell for fibromyalgia will be presented at two upcoming pain medicine conferences. Quell is a transcutaneous electrical nerve stimulator indicated for symptomatic relief and management of chronic lower extremity pain and is available over-the-counter.

NeuroMetrix's Nerve Stimulator Shows Mixed Outcomes In Fibromyalgia Trial

NeuroMetrix, Inc.'s (NURO) CEO Shai Gozani on Q1 2021 Results - Earnings Call Transcript

WOBURN, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2021. The Company is a leader in proprietary non-invasive medical devices for the diagnosis and treatment of pain and neurological disorders.

NeuroMetrix Reports Q1 2021 Financial Results

WOBURN, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 first quarter financial results before the opening of the market on April 22, 2021. The Company will host a conference call at 8:00 a.m., Eastern Time on April 22, 2021 to discuss its financial results as well as business developments affecting the Company.

NeuroMetrix, Inc. Announces Date for First Quarter 2021 Financial Results Conference Call

NeuroMetrix, Inc. (NURO) CEO Dr. Shai Gozani on Q4 2020 Results - Earnings Call Transcript

WOBURN, Mass., Jan. 28, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and year ended December 31, 2020. The Company is focused on the development and global commercialization of non-invasive medical devices for the diagnosis and treatment of disorders involving the nervous system.

NeuroMetrix Reports Q4 and Full Year 2020 Financial Results

WOBURN, Mass., Jan. 22, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2020 fourth quarter and full year financial results before the opening of the market on January 28, 2021. The Company will host a conference call at 8:00 a.m., Eastern Time on January 28, 2021 to discuss its financial results as well as business developments affecting the Company.

NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2020 Financial Results Conference Call

NeuroMetrix (NASDAQ: NURO) is currently up 45.17% to a price of $3.04. The stock's volume is currently 62.04 million, which is roughly 32668.92% of its recent 30-day volume average of 189.91 thousand.

Why NeuroMetrix's Stock is Up During Today's Session

NeuroMetrix (NURO) stock is on the rise Tuesday with heavy trading despite a lack of news concerning the medical device company. The post NURO Stock: 10 Things for Potential Investors to Know About NeuroMetrix appeared first on InvestorPlace.

NURO Stock: 10 Things for Potential Investors to Know About NeuroMetrix

NeuroMetrix, Inc. (NURO) CEO Dr. Shai Gozani on Q3 2020 Results - Earnings Call Transcript

WOBURN, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended September 30, 2020. The Company is a leading developer of neurostimulation-based medical devices that are used to diagnose and treat chronic health conditions.

NeuroMetrix Reports Q3 2020 Financial Results

WOBURN, Mass., Oct. 15, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that it plans to issue its 2020 third quarter financial results before the opening of the market on October 22, 2020. The Company will host a conference call at 8:00 a.m., Eastern Time on October 22, 2020 to discuss its financial results as well as business developments affecting the Company.

NeuroMetrix, Inc. Announces Date for Third Quarter 2020 Financial Results Conference Call

Aptiv Holdings Ltd

Bayerische Motoren Werke AG

Ford Motor Company

Fiat Chrysler

General Motors

Hyundai Motor Company

Nissan Motor Co Ltd

Toyota Motor

Tesla

Volkswagen AG

Who Will Win The Lucrative Autonomous Vehicles (Robotaxis) Race?

WOBURN, Mass., Sept.  22, 2020  (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported the launch of the Quell Watch App, now available for download from the Apple App store.

NeuroMetrix Launches Quell® App for Apple Watch®, the First Smartwatch App for an Over-the-Counter Pain Relief Device

WOBURN, Mass., Sept.  21, 2020  (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office will issue on September 22, 2020 U.S. Patent No. 10,780,269 titled “Apparatus and Method for Relieving Pain Using Transcutaneous Electrical Nerve Stimulation."

NeuroMetrix Announces Issuance of New U.S. Patent for Quell® Wearable Technology

WOBURN, Mass., Sept.  04, 2020  (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported that it will present a scientific poster at the PAINWeek 2020 Live Virtual Conference to be held September 11 - 13.  PAINWeek is the preferred resource in the U.S. for frontline practitioners treating acute and chronic pain.

NeuroMetrix Reports Scientific Presentation at the PAINWeek 2020 Live Virtual Conference

WOBURN, Mass., Sept.  01, 2020  (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported the publication of a large study demonstrating that DPNCheck effectively determines the severity of diabetic peripheral neuropathy (DPN).  DPNCheck is a widely used point-of-care test that provides fast, accurate and cost-effective screening, diagnosis and monitoring of peripheral neuropathies.  It is often used to stage the severity of DPN, which is the most common specific cause of peripheral nerve disease and a ubiquitous long-term complication of diabetes that may lead to foot ulcers and amputation.

NeuroMetrix Reports Publication of Study Validating DPNCheck® Staging of Diabetic Peripheral Neuropathy Severity

WOBURN, Mass., Aug.  20, 2020  (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell device will be used in an NIH-funded, multi-site randomized controlled trial (RCT) of the efficacy of transcutaneous electrical nerve stimulation (TENS) for chemotherapy-induced peripheral neuropathy (CIPN). The principle investigator is Dr. Jennifer Gewandter of the University of Rochester School of Medicine and Dentistry. The trial leverages the National Cancer Institute (NCI) Community Oncology Research Program (NCORP).

NeuroMetrix Reports that Quell® is to be Evaluated for Chemotherapy-Induced Peripheral Neuropathy in NIH-Funded Clinical Trial

WOBURN, Mass., Aug.  10, 2020  (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) published an infographic on chronic knee pain ( available here ) and provided an update on how Quell technology addresses knee pain.

Quell® Fills Unmet Need for Chronic Knee Pain Relief that is Drug-Free

NeuroMetrix's (NURO) CEO Shai Gozani on Q2 2020 Results - Earnings Call Transcript

News for NeuroMetrix Stock (NURO)